Cancer Screening Company GRAIL Completes $300 Million C Series Financing
Recently, GRAIL, a cancer screening company, announced that it has completed a $300 million C-round super-financing. The leading investor in this round of financing is Huiqiao Capital, and Tonghe and Chenghao Capital also participated in the lead. In addition, Bluepool Capital, China Merchants Securities International, CRF Investment, Huangpujiang Capital (HPR), ICBC International, Sequoia Capital China, and Yaoming Mingji also participated in the investment. GRAIL won $900 million in the B round last year. Financing. It is reported that Grail was founded by Illumina and ARCH Venture Partners with a total investment of 100 million US dollars. Bill Gates, Bezos Expeditions, and Sutter Hill Ventures are also involved in the investment. Grail plans to launch a variety of early cancer detection in 2019. The product, priced at less than $1,000, is designed to screen out patients without cancer symptoms so that cancer can be detected in the early stages of the highest cure rate. Illumina CEO Jay Flatley is also the chairman of Grail. After obtaining financing, GRAIL launched the CCGA program, which aims to create a circulating cell-free DNA atlas (CCGA) that describes and compares the heterogeneity or variability of ctDNA in healthy and cancer patients. The map will support Grail's test product development program, enabling it to accurately calibrate test products to identify patterns in healthy people that indicate the tumor is forming. To create CCGA, Grail worked with multiple academic centers to recruit a total of 10,000 subjects and analyzed their blood samples using a comprehensive targeted panel and ultra-deep sequencing strategy. The company plans to track subjects for five years and analyze changes in their circulating DNA patterns and levels. In this study cohort, 7,000 subjects will be cancer patients and another 3,000 subjects will be healthy controls. In addition, GRAIL has launched a large-scale clinical trial called STRIVE. With the assistance of institutions such as the Mayo Clinic, the clinical trial will recruit up to 120,000 women and analyze their free nucleic acids (cell-free). Numeric acids, cfNA), develop and validate an early diagnosis of breast cancer. It is understood that up to now, CCGA and STRIVE clinical trials have recruited more than 73,000 patients and will complete the recruitment of the remaining patients this year as planned. Jeff Huber, CEO of Grail, once said, "There are two main challenges in early detection of cancer: one is cancer heterogeneity. Given the heterogeneity and the fact that we want to detect cancer at its earliest stages, we must study the genome very extensively. To find out where the mutation occurred, and to detect it, the other is depth. Our goal is to be able to detect some molecules in a blood sample that can indicate cancer at the earliest stage, so our sequencing depth is deeper than other companies. An order of magnitude, we can generate terabytes of data for each test sample." According to Ken Drazan, president of GRAIL, “Many of our investors are concerned about Asia. This has a natural fit with us. We plan to enhance our capabilities and operations in these regions and launch the first early in Hong Kong later this year. Diagnose products for nasopharyngeal cancer."
Organic mung bean starch is a kind of powder formed by the precipitation of mung bean after soaking and grinding with water. Our organic mung bean starch follows the traditional processing ideas and combines modern industrial technology to achieve a more efficient, safer, and more hygienic processing level. The characteristics of mung bean starch are sufficient stickiness, low water absorption, white and shiny color.
Mung bean (Vigna radiata) is a plant in the legume family. Mung beans are mainly grown in India, China, and Southeast Asia. The Chinese have grown mung beans for nearly 2,000 years. They are ubiquitous in China, and there are many types, and numbers. Mung beans are also grown in other countries/regions in South Asia, North America, Brazil, and Europe. The main provinces for mung bean cultivation in China are Anhui, Henan, Hebei, Hubei, Liaoning, Shanxi, Shaanxi, and Sichuan.
The nutritional value of mung bean starch is very high, and its uses are also very wide. For example, mung bean starch has antibacterial, antibacterial, hypolipidemic, antitumor, and detoxification effects.
Mung bean starch contains a considerable amount of oligosaccharides (pentosan, galactan, etc.). These oligosaccharides are difficult to be digested and absorbed because the human gastrointestinal tract does not have a corresponding hydrolase system, so mung bean starch provides a lower energy value than other grains and has an adjuvant therapy effect for obese and diabetic patients.
Mung Bean Starch,Organic Mung Bean Starch,Mung Bean,Mung Bean Starch Organic Organicway (xi'an) Food Ingredients Inc. , https://www.organic-powders.com